JCG
EPRS

JHL Capital Group’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

JHL Capital Group’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-55,000
Closed -$243K – 30
2015
Q3 		$243K Buy
+55,000
New +$323K 0.03% 24

Other funds holding EPRS

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JHL Capital Group's EPRS Position: Q4 2015 in Review

JHL Capital Group sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q4 2015, closing a stake of 55,000 shares — an estimated $243K sold.

JHL Capital Group first reported a position in EPRS in Q3 2015 and held it in 1 quarter. The position peaked at $243K in Q3 2015. 45 funds tracked by Wall St. Rank hold EPRS as of Q4 2015.

  • JHL Capital Group reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q4 2015 after selling out during the quarter.
  • JHL Capital Group sold 55,000 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q4 2015, an estimated $243K.
  • JHL Capital Group first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q3 2015 and held it in 1 quarter.
  • JHL Capital Group's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $243K in Q3 2015.
  • 45 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q4 2015.

Based on JHL Capital Group's 13F filing for Q4 2015, filed 16 Feb 2016.